Industry / innovation partners

Pembrolizumab Just Lost a Head-to-Head Survival Fight

Novo’s $1.4B Orbis Deal Bets on a New Route to Oral Cardiometabolic Drugs

HER2-Mutant Lung Cancer Just Moved Into First Line

Breast Cancer Just Proved Why Biomarker Selection Matters

Epilepsy Innovation Just Hit a Safety Wall

Obesity treatment is becoming a portfolio, not a product. Lilly’s EASD lineup shows what comes next

The Recall Is Still In The Freezer.

The mRNA Cancer Vaccine Story Just Got Less Comfortable

Three drugs, three biological hypotheses: Kardigan is putting precision cardiology to the test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
